EQA of malignant mesothelioma marker analyses.

Mogens_Vyberg

Dr. Mogens Vyberg graduated in 1973, completed residencies in Anatomic and Clinical Pathology at hospitals associated with University of Copenhagen, and was board-certified 1984. Since 1988 he has been senior consultant at the Institute of Pathology, Aalborg Hospital and was appointed as professor of clinical pathology at Aalborg University in 2012.
Dr. Vyberg’s main research fields and clinical expertise are immunohistochemistry and gastrointestinal, liver and brain pathology. He is author and co-author of more than 80 scientific papers and several book chapters in these fields as well as the text book Compendium of Applied Immunohistochemistry (Danish; English version scheduled for 2016). He is head of the Laboratory for immunohistochemistry/R&D, which carries out quality control and protocol optimization for the world’s leading diagnostics companies.
Dr. Vyberg is co-founder and scheme director of the international organization Nordic Immunohistochemical Quality Control (NordiQC), which was established in 2003 with Aalborg Hospital as its domicile and currently serves about 700 pathology laboratories from more than 40 countries.

EQA of malignant mesothelioma marker analyses.

Abstract: Diagnostic markers for identification of malignant mesothelioma include: Calretinin (CR), Podoplanin (PDP) and Wilms’ tumour-1 (WT-1). These have all been included in one or more NordiQC challenges, the results of which are detailed on www.nordiqc.org. For all tests, major reasons for insufficient stains were too low concentration of the primary antibody and use of low sensitive detection systems. Furthermore, less successful performance on the Ventana BenchMark platform  were seen with clone DAK-Calret 1 (for CR), clone D2-40 (for PDP) and clone 6F-H2 (for WT-1).

Ver página web del evento.